The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The trial enrolled patients with standard-risk disease who were not undergoing up-front autologous stem-cell transplantation. Following induction treatment with a proteasome inhibitor–lenalidomide combination, a total of 516 patients underwent randomization at the end of induction.
From EHA 2026, Dr. Komrokji shares the latest research in MDS, and his thoughts on what is next in the field.
Ofirnoflast, a first-in-class, oral, allosteric inhibitor of NEK7, was evaluated in 37 patients and demonstrated clinically meaningful results, according to the investigators, who shared their results at the 2026 EHA Hybrid Congress.
The speakers highlighted how combining these powerful drugs into fixed-duration regimens could help patients achieve long-term remissions and move closer to a cure.
The panel also discussed the success of combining teclistamab and daratumumab for functional high-risk patients who historically experience poor outcomes.
The US Food and Drug Administration has accepted a new drug application for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
![Insider_YT_Feature_Pannunzio_CLFR2_400x400[15]](https://sohoinsider.com/wp-content/uploads/2026/06/Insider_YT_Feature_Pannunzio_CLFR2_400x40015.png)
